Stockreport

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

KIRIN HLDGS CO LTD S/ADR  (KNBWY) 
US:NASDAQ Investor Relations: kirinholdings.co.jp/english/ir
PDF First and only Adenosine A2A receptor antagonist for use in Parkinson’s Disease in the U.S. TOKYO--(BUSINESS WIRE)--Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) an [Read more]